Brief: Lantheus Announces FDA Acceptance of New Drug Application for MK-6240
28/10/2025 12:33
Oct 28 (Reuters) - Lantheus Holdings Inc LNTH.O: LANTHEUS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR MK-6240, A PET IMAGING AGENT TARGETING TAU IN ALZHEIMER’S DISEASE LANTHEUS HOLDINGS INC - FDA SETS PDUFA TARGET DATE FOR AUGUST 13, 2026 Source text: ID:nGNX5GpcMg Further company coverage: LNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsStreet View: Lantheus' tumor kit setback seen as temporary, with growth catalysts still ahead
Brief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say